EXPRESSION STREAM
2nd Annual
Purifying Antibodies May 3 - 4
As demand increases, processes need to escalate in order to produce large numbers of purified antibodies. Currently, between expression and purification, almost half of the product is lost. Purification processes need to be improved to enhance recovery, while maintaining antibody quality. The “Purifying Antibodies” meeting will feature leaders in the field who will share their case studies and experiences both innovating traditional purification techniques and also employing non-traditional approaches that show promising results. The focus for the differing methods discussed will be “Streamlining Processes” with the aim of providing researchers a greater harvest.
Day 1 | Day 2 | Download Brochure
THURSDAY, MAY 3
12:00 pm Registration
1:30 Chairperson’s Opening Remarks
David O’Connell, Ph.D., Senior Scientist, Conway Institute of Biomolecular & Biomedical Research, School of Medicine, University College, Dublin
» 1:40 KEYNOTE PRESENTATION
Novel Molecules, Novel Purification Processes?
 David J. Roush, Ph.D., Senior Investigator, BioProcess, Protein Purification Development, Merck Research Labs (biography)
Advances in cell culture/fermentation development and a plethora of options for expression systems have eliminated most of the upstream productivity bottleneck. The current challenge is to globally optimize the productivity of the entire process while maintaining product quality and cost targets and maximizing facility utilization. The increased diversity of molecular types and truncated development times require a reassessment of a platform purification approach and a collaborative, strategic evaluation of new purification modalities.
|
» 2:10 Featured Presentation
Streamlining Processes and Process Development with High-Throughput Screening and Analytical Tools
 Joey M. Studts, Ph.D., Director, Protein Science, Boehringer Ingelheim Pharma GmbH & Co. (biography)
To efficiently integrate technologies, the Protein Science Department has developed the BI-PurEx Strategy. This strategy ensures a rapid, effective and flexible development timeline and an efficient process to meet the demands at any stage in product development, from clinics to market. This presentation will demonstrate how the integration of data from high-throughput biophysical assays and automated screening is used to develop critical process knowledge and a fast track to success without impacting the critical path to clinical trial material.
|
2:40 Parallel Protein Purification at the mg Scale
Robert Arduini, Senior Scientist, Biogen-Idec
Peter Nollert, Ph.D., Director, Membrane Protein Technologies, Emerald Bio
Many modern biologics discovery pipelines require the preparation of numerous variants of a particular target protein on the milligram scale. While conventional chromatographic methods can readily be applied to such protein targets, scaling up the number of purifications has become a bottleneck in many protein purification laboratories. In order to address this challenge, we have developed an automated protein purification system, the Protein Maker, for the simultaneous chromatographic purification of up to 24 different proteins. This instrument uses standard 1 mL or 5 mL bed volume chromatography columns, allows multiple load, wash, and elution buffers in independent lines for up to 24 different protein samples in parallel. This presentation explains the utility of this instrument within the Emerald Bio gene-to-structure workflow for target scouting, as well as for parallel protein purification. In a second portion of this presentation, the application of the Protein Maker instrument within the Biogen Idec Drug Discovery Department will be illustrated using results gained with 2 kinase targets and antibody Fab fragments.
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00-5:00 Problem Solving Breakout Discussions
Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.
Possible Impact of Molecular Modeling on Antibody Purification Processes
Moderator: Carlo Cavallotti, Ph.D., Associate Professor, Dipartimento di Chimica, Materialied Ingegneria Chimica “G. Natta,” Politecnico di Milano
• What is the best way to use molecular modeling to improve the performances of separation processes?
• How can molecular modeling predictions be validated in order to establish an ‘experiment-model-prediction’ virtuous cycle?
• Which are the aspects of antibody purification that would benefit mostly from a molecular level understating of the involved phenomena?
Jason and the Argonauts MMXII-The Quest for the Golden Antibody
Moderator: Dan L. Crimmins, Ph.D., Senior Scientist, Pathology & Immunology, Lab & Genomic Medicine, Washington University School of Medicine
• Commercial Ab's are a "hit or miss" proposition.
• Considerable time and resource are wasted.
• How can investigators change this?
• Require greater validation from vendors.
• Availability of Ab specific, detailed application protocols.
• Potentially a "win-win" business proposition.
How Pure is Pure?
Moderator: David O’Connell, Ph.D., Senior Scientist, School of Medicine, University College Dublin
• What are acceptable limits of purity
• Rapid methods for establishing level of purity
• The need for high sensitivity assessment e.g., MS based analysis
• Experiences of different tag systems
Membrane Protein Crystallization using Lipidic Mesophase
Moderator: Tim Craig, Ph.D., Senior Scientist, Emerald Bio
|
5:00 Close of Day
Day 1 | Day 2 | Download Brochure